A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

Study Summary

The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.

Conditions

Respiratory Syncytial Virus

Interventions / Drugs

mRNA-1345

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment507 participants

Primary Completion—

Lead SponsorModernaTX, Inc.

Data Retrieved2026-04-11 02:55:38.209111+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.